BPC-157 capsules: is oral BPC-157 absorbed, and do the pills work?

Capsules are the form of BPC-157 that looks most like an ordinary supplement, and that is where most of the confusion starts. Nobody has shown that a capsule works in people, or even that a useful amount gets into the blood. The case for capsules rests on one real fact, that BPC-157 survives stomach acid, plus a large gap: FDA found no human study of oral BPC-157 at all. BPC-157 is not FDA-approved by any route.

What is the evidence for oral BPC-157?

The evidence is rat studies, and none of it measured absorption.

The 2018 Zagreb review in Current Pharmaceutical Design reports benefit by injection, by mouth and locally across many rat models. The work comes mainly from one laboratory, and none of it measured blood levels after an oral dose.

Humans have swallowed BPC-157 in one planned study. A phase 1 trial registered in 2015 (NCT02637284) set out to give 1 mg tablets to 42 healthy volunteers in Tijuana, Mexico, and to measure safety and blood levels. Its status is unknown, no results have been posted, and FDA could not find a publication. It is the study that could have answered the absorption question, and nobody has seen what it found.

Does surviving stomach acid mean it gets absorbed?

No. Stomach-acid stability only gets a peptide through the first obstacle. A 2026 pharmaceutics review of BPC-157 said gastric stability “is not sufficient to establish oral bioavailability for a peptide therapeutic.” Oral bioavailability means the share of a swallowed dose that reaches the bloodstream. After the stomach, a peptide still has to survive intestinal enzymes, cross the gut wall and pass through the liver. The same review lists oral bioavailability “in any species” among the data that do not exist, and it notes that approved oral peptides such as oral semaglutide needed special formulation to reach the blood at all.

FDA’s July 2026 review found no human pharmacokinetic data after oral dosing. In its two enema studies, BPC-157 was not detected in the blood, or most readings were too low to measure, which led FDA to say it does not appear to be absorbed by that route. Animal data offer little comfort: after intravenous dosing, the half-life was 5.3 minutes in dogs and 15.2 minutes in rats.

A gut-only effect is possible in theory, since a capsule could act locally without reaching the blood. That would be a reason to doubt claims about tendons and joints, and it remains untested in people either way.

What does the HHS policy say about oral BPC-157?

The October 2026 HHS policy sets a higher bar for oral products than for injections. As of November 2, 2026, HHS says it does not intend to take enforcement action against compounding of BPC-157 acetate for oral use when ten conditions are met. One of them is specific to oral forms. It says that achieving adequate oral bioavailability of peptides “is inherently difficult and complex,” so the compounder is expected to keep documentation confirming that the specific formulation reaches adequate oral bioavailability in humans.

Two practical points follow.

• The data may not exist. Since FDA found no human oral pharmacokinetic data for BPC-157, it is hard to see where that documentation would come from. Lawyers at Fox Rothschild note the policy does not define “adequate” or say what paperwork is enough, and that without documentation, oral products fall outside it.
• A compounded capsule and a supplement capsule are different things. The policy concerns drugs compounded for a named patient on a valid prescription, with a certificate of analysis from an FDA-registered manufacturer. A bottle sold over the counter is none of those.

The usual limits apply. BPC-157 remains unapproved and off the 503A bulks list, no rule has been proposed, FDA has not reviewed any compounded product, the policy is not binding and can be revisited, and states can be stricter. The evidence for capsules is unchanged by any of it.

The arginate salt claim

Some capsules are sold as “BPC-157 arginate” or “stable” BPC-157, with claims that the arginine salt resists breakdown better than the acetate. We found no peer-reviewed study testing those claims. FDA’s 2026 review evaluated only the free base and the acetate, and it treats different salt forms as different substances. The HHS policy names only the acetate. Until someone compares salt forms for stability and absorption, the claim is marketing.

Is a BPC-157 capsule a lawful supplement?

Capsule products are usually labeled as dietary supplements, but that does not make them lawful supplements.

• What FDA has said. FDA’s July 2026 briefing states that BPC-157 “is marketed in the United States as an ingredient in dietary supplement products formulated as oral capsules and tablets” and that there is no USP dietary supplement monograph for it. FDA has also treated BPC-157 products as unapproved new drugs in warning letters, such as a 2023 letter citing claims about ulcers, irritable bowel syndrome and Crohn’s disease.
• What a dietary ingredient is. Under federal law, a dietary ingredient is a vitamin, mineral, herb or other botanical, amino acid, or certain other dietary substances and their concentrates or extracts. The law also generally excludes ingredients first authorized for investigation as a drug, with exceptions.
• What we could not find. We found no FDA document ruling directly on whether BPC-157 can be a dietary ingredient. The Defense Department’s Operation Supplement Safety program states that “BPC-157 is not a dietary ingredient” and that it is an unapproved drug, and it appears on the Department’s prohibited dietary supplement ingredients list.
• No pre-market check. FDA states that it “does not have the authority to approve dietary supplements before they are marketed.” A capsule on sale has not been reviewed by anyone just because it is on sale.

A product marketed to heal ulcers, gut disease or injuries is making a drug claim, and FDA’s warning letters in 2023 and 2026 treated BPC-157 marketed that way as an unapproved new drug.

What is actually in the capsule?

We could not find any published independent analysis of BPC-157 capsules sold in the United States. What is known about quality comes from FDA’s review:

• BPC-157 has no USP monograph, so there is no official standard for identity, purity or strength.
• FDA judged it “not well-characterized”: names are used inconsistently, and data needed to establish identity, purity and quality for the proposed dosage forms, capsules included, were lacking or inadequate, including tests for peptide impurities and microbial quality.
• FDA’s food and supplement adverse event database held three reports involving BPC-157, all complicated by its use in multi-ingredient supplements.

In practice, a capsule’s label claim has not been verified by anyone outside the seller. Nominators proposed capsule strengths to FDA, and FDA found capsules marketed online with directions for use. There is no evidence that any of those amounts does anything in a person, and the BPC-157 dosage page explains why no dose has been established.

Are capsules safer than injections?

Perhaps, in one narrow respect, though nobody has measured it. FDA said the inherent immune risk of oral BPC-157 is likely low, while raising concerns about peptide-related impurities. Capsules also avoid needle-related infection. The bigger question of what long-term oral use does has not been studied, and FDA found no animal toxicology for the oral route. Side effects by route are covered in the BPC-157 side effects guide.

Banned in sport, and off-limits as research product

The 2026 WADA Prohibited List names BPC-157 under class S0, prohibited at all times, whether swallowed or injected. Capsules sold “for research use only” are not legal to use on people: 21 CFR 312.160 allows shipment only for laboratory animal or test-tube work, and the HHS policy gives such products no cover. The FDA status tracker follows the rulemaking.